# OnCo record paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015" ;
schema:name "Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)"@en ;
schema:description "The US trial of 443 women that showed adding carboplatin to pre-surgery paclitaxel, doxorubicin and cyclophosphamide raised complete tumour disappearance in breast and nodes from 41 to 54 percent, at the cost of more low blood counts and skipped doses; it and GeparSixto made platinum standard."@en ;
schema:url ;
schema:dateModified "2026-09-24"^^xsd:date ;
schema:citation , , ;
onco:tag "tnbc-evidence" ;
schema:sameAs ;
schema:datePublished "2015"^^xsd:gYear ;
schema:author "Sikov WM, Berry DA, Perou CM, et al." ;
onco:related ;
onco:cancers ;
onco:technologies ;
onco:drugs , , , ;
onco:terms , ;
onco:trials , ;
onco:people ;
onco:journals .